CD73 on cancer-associated fibroblasts enhanced by the A2B-mediated feedforward circuit enforces an immune checkpoint

Abstract

CD73, an ecto-5′-nucleotidase (NT5E), serves as an immune checkpoint by generating adenosine (ADO), which suppresses immune activation through the A2A receptor. Elevated CD73 levels in tumor tissues correlate with poor clinical outcomes. However, the crucial source of CD73 activity within the tumor microenvironment remains unspecified. Here, we demonstrate that cancer-associated fibroblasts (CAFs) constitute the prominent CD73hi population in human colorectal cancers (CRCs) and two CD73 murine tumor models, including a modified CRC. Clinically, high CAF abundancy in CRC tissues correlates strongly with elevated CD73 activity and poor prognosis. Mechanistically, CAF-CD73 expression is enhanced via an ADO-A2B receptor-mediated feedforward circuit triggered by tumor cell death, which enforces the CD73-checkpoint. Simultaneous inhibition of A2A and A2B pathways with CD73-neutralization synergistically enhances antitumor immunity in CAF-rich tumors. Therefore, the strategic and effective targeting of both the A2B-mediated ADO-CAF-CD73 feedforward circuit and A2A-mediated immune suppression is crucial for improving therapeutic outcomes.

Introduction

CD73 is an ecto-5′-nucleotidase (NT5E) that generates extracellular adenosine (eADO) through coordination with ecto-nucleoside ATPases, including ectonucleoside triphosphate diphosphohydrolases1 (ENTPD1, NTPDase1, CD39) and NTPDase2 (CD39L1)1,2,3. Extracellular ADO imposes immune inhibition via the adenosinergic A2A receptor4,5,6. Therefore, CD73, as a rate-limiting enzyme of eADO generation, serves as a crucial metabolic and immune checkpoint by diverting the eATP-triggered immune activation signal to eADO-induced immunosuppression. Clinically, elevated CD73 levels in the tumor tissue of several cancer types, including breast, ovarian, and colorectal cancers (CRC), are linked to poor patient survival7,8,9, which underscores the crucial role of CD73 in tumor progression. Currently, CD73 neutralization therapy, either alone or in combination with an A2A antagonist, is being tested in clinical trials. However, the crucial populations targeted by anti-CD73 within the tumor microenvironment (TME) are not clearly defined. Although CD73 expression had been observed on some tumors, such as melanomas and prostate cancers, and tumor-infiltrating leukocytes (TILs), especially regulatory T cells (Tregs)2,7,10,11,12, experimental model systems using Cd73null mice clearly suggest a crucial contribution of host CD73 activity in the non-hematopoietic compartment to the observed immunosuppression12,13,14. Aside from endothelial vasculature12, CD73 activity in cancer-associated fibroblasts (CAFs), which are the dominant non-hematopoietic stromal cells in many tumors15,16,17, remains largely undefined.

CAFs are known to be crucial for supporting tumor progression, chemoresistance, metastasis, and maintenance of cancer stem cells through the production of growth factors, chemokines, and extracellular matrix (ECM)15,16,17,18,19. Recent evidence suggests that CAFs also play active roles in shaping the immune landscape of the TME via ECM-regulated immune cell anchorage and trafficking and via suppression of immune activation15,16,17. Although our understanding of the origin and characteristics of CAFs is still evolving, existing evidence suggests that CAFs are derived from normal fibroblasts (FBs), including tissue resident FBs and bone marrow-derived mesenchymal stem cells (MSCs), which are subsequently modulated by factors and cellular interactions in the TME20,21. Interestingly, CD73 has been used as one of the MSC markers22, which compelled us to examine CD73 expression on CAFs and whether CAF-CD73 in the TME enforces the immune checkpoint pathways.

Using clinical CRC specimens, publicly accessible transcriptome datasets from human CRC-tissues, CRC-CAFs, and fresh CAFs from mouse tumor models, our comparative investigations demonstrate that CAFs are the prominent CD73hi cells in the TME. Compared with other cellular constituents within the TME, CD73 expression and bioactivity on CAFs are significantly higher and high levels of CD73 in the TME of human CRCs are associated with high CAF abundancy and immunosuppression. Mechanistically, in vivo studies reveal that CAF-CD73 is dynamically regulated by eADO generated in the TME via activation of the A2B receptor. Thus, this CAF-CD73-ADO-A2B feedforward circuit enforces the CD73-checkpoint and works synergistically with the ADO-A2A-mediated T cell/immune suppression through two functionally non-redundant processes. Therapeutically, simultaneous implementation of A2A and A2B antagonism, especially in combinations with CD73 neutralization, leads to a significant improvement in tumor control. Using an engineered CD73-MC38 murine CRC model, we further demonstrate that the collaborative effects of andenosinergic antagonism and CD73-neutralization on tumor control are more effective in the CAF-rich TME.

Results

CD73high cells in the human CRCs are mostly activated FBs

Clinical and molecular investigations demonstrate that CAF abundancy in CRCs is associated with poor prognoses23,24. Our examination of 25 formalin-fixed paraffin-embedded (FFPE) or cryopreserved human CRC adenocarcinoma specimens obtained from our tumor bank revealed that more than 50% of the CRCs manifested moderate to high stromal content via H&E staining (Fig. 1a). Multiplex immunohistochemistry (IHC) staining of the FFPE specimens (Fig. 1a) and conventional immunofluorescence (IF) staining of the frozen specimens (Supplementary Fig. 1a) verified the abundant activated FBs, i.e CAFs, using α-smooth muscle actin (α-SMA) or ER-TR7 for reticular fibers25 as markers, respectively. Quantitative analysis of CD73 expression and distribution on α-SMA+ CAFs, CD11b+ myeloid, and CD3+ T cells in the IHC-stained specimens via a computer-assisted program indicated that 75–90% of the CD73+ signal distributed on α-SMA+ CAFs (Fig. 1b), while <5% of the CD73+ signal co-localized with CD11b+ myeloid and CD3+ T cells (Fig. 1c). Similarly, IF-stained frozen specimens confirmed predominate CD73 expression on ER-TR7+ CAFs and minimal overlap with CD45+ TILs (Supplementary Fig. 1c, d). Moreover, limited CD73 expression was observed in EpCAM+ tumor cells in majority of the specimens (Fig. 1d, e), except for a few CAF-rich specimens where CD73hi signal was detected in the lumina (Supplementary Fig. 1e). These histological assessments demonstrate that CD73 protein expression is highly concentrated on fibroblastic stroma or CAFs. Next, we analyzed the publicly accessible human transcriptome dataset of FACSort-purified paired CRC fibroblastic stroma (CAFs), TILs, and epithelial tumor cells (GSE39396), which substantiates the significantly higher NT5E mRNA levels in CRC-CAFs than in tumors and TILs (Fig. 1f). Together, these results strongly suggest that CD73hi expression is a unique characteristic of human CRC-CAFs.

Fig. 1: Elevated CD73 levels in human CRCs are associated with CD73hi-CAF abundancy and poor clinical outcomes.
figure1

a Histological H&E examination (left) and multiplex immunohistochemistry (IHC) staining of CD73 (red), a-smooth muscle actin (a-SMA, green), CD11b (cyan), and CD3 (gray) were performed with de-identified FFPE CRC-specimen. Nuclei were counterstained with DAPI (blue). Representative images illustrate the level of CD73 expression and its bio-distribution on CAFs (α-SMA+), CD11b+ myeloid, and CD3+ T cells in CAF-rich, moderate, and poor specimens. Scale bars, 100 μm. b, c Randomly selected and evenly distributed areas (~5 × 105 mm2) from each multiplex IHC-stained CRC specimen were analyzed for the percentage of CD73+ signal that distributed on α-SMA+ b, CD11b+, and CD3+ cells c among the total CD73+ region in each area, which was set as 100%, was calculated and plotted. d Multiplex IHC staining was performed to determine tumor (EpCAM, magenta), CD73 + (red) cells, and CAFs (α-SMA, green) distribution and their potential co-localization. Scale bars, 50 μm. e The percentage of CD73+ signal on EpCAM+ tumors against total CD73+ region was presented. f CD73 (NT5E) gene expression in paired purified CRC-CAFs (red box), TILs, and tumors from published dataset (GSE39396) was compared. g Principle component analysis was performed with a published CRC cohort dataset (GSE39582) of 557 CRC specimens. The NT5Ehigh (red) and NT5Elow (blue) specimens were first defined by their CD73 expression in the top 20% and bottom 20% level, respectively, and clustered against a group of 18 fibroblast-specific (FB) genes that shows a positive correlation and against a group of 15 pre-defined group immune effector function associated genes as Immune response genes that reveals negative association. h The Kaplan–Meier survival curve demonstrates clinical correlation of NT5Ehigh (red) and NT5Elow (blue) expression in CRC patients (GSE 39582) with event-free survival. Data depict mean ± SEM. Unpaired Student’s t-test for b, c, e and paired Student’s t-test for f. Source data are provided in the Source Data file.

Elevated tumor CD73 levels are associated with poor clinical outcomes in several tumor types7,9,26,27,28. Nevertheless, most of the correlative studies were based on CD73 expression in unfractionated tumor tissues. To determine whether a specific algorithm could be formulated to evaluate relative CAF abundancy from the published datasets of total tumor tissues, we defined an 18-gene set of FB-specific genes based on a previous report of highly expressed genes in CRC-CAFs23 and those commonly used to define CAFs or FBs17,20,23 (Source data for supplementary figures). Likewise, a set of 15 immune response-associated genes was designated from the common genes associated with immune effector, signaling, and function (Source data for supplementary figures). The specificity of these gene sets was validated by at least a two-fold higher expression in purified CRC-CAFs or CRC-TILs, respectively, and distinct clustering of CAFs, tumors, and TILs based on the expression profiles (GSE39396, Supplementary Fig. 1f). Using these two gene-sets, we performed a principal component analysis (PCA) of a CRC transcriptome dataset with 585 patients (GSE39582), and clustered the data at the top 20% of NT5E levels (NT5Ehigh) and bottom 20% of NT5E (NT5Elow) groups. As expected, using the FB-gene set as the first principle component (PC #1), NT5Ehigh and NT5Elow groups were segregated into the FB-high and FB-low clusters, respectively (Fig. 1g), confirming a positive correlation between CD73 expression and CAF abundancy. Likewise, clustering against the immune response gene set positioned the NT5Ehigh and NT5Elow into the immune-response low and high clusters, respectively, supporting a negative correlation (Fig. 1g and Supplementary Fig. 1g). Importantly, high NT5E levels in these 557 patients correlated robustly with poor clinical outcomes (Fig. 1h). These results suggest that high levels of CD73 expression in the human CRC TME correlate positively with CAF abundancy, augmented immunosuppression, and poor prognosis.

CAFs are the major source of CD73 activity in the EG7 TME

For comparative analysis of the CD73 expression and function among all cellular subsets of the TME, we employed ectopic murine tumor models. Among the MC38-CRC, EG7 T-lymphoma, and B16 melanoma models, CAFs were mostly CD73hi cells compared with TILs and tumors (Fig. 2a, Supplementary Fig. 2a, b). Unlike CD73−/lo human CRC-adenocarcinomas (Fig. 1), MC38 tumors were CD73+ with a comparable level of CD73 to that of MC38-CAFs (Supplementary Fig. 2b). Because EG7 tumors were CD73 with abundant CAFs and CAF-CD73 levels were comparable to those seen in human CRCs (Supplementary Fig. 2b–d), we first employed the EG7 model. IF staining confirmed that CD73hi signal distributed throughout the EG7 TME, mostly overlapped with the ER-TR7+ CAFs (Fig. 2c). Computer-assisted image analysis revealed that EG7-CAFs occupied up to 30% of the area (Fig. 2b, d) despite only constituting 2–3% of the cellularity determined by flow cytometry (FACS, Fig. 2a, b). In contrast, CD11b+ myeloid and CD3+ T cells only covered ~10% and 0.5% of the area although they accounted for ~30% and 5% of the cellularity, respectively (Fig. 2b, d). Therefore, similar to human CRC-CAFs, EG7-CAFs exemplify a unique CD73hi/+ population that forms an extensive network within the TME.

Fig. 2: CAFs in the murine TME are CD73hi cells with a superior capacity for ADO generation than TILs.
figure2

a EG7 tumors established s.c. in C57BL/6 WT mice for 15 days were used for assessment of cellular constituents of the EG7 TME via FACS as CD11b+ myeloid cells, CD45+CD11b EG7-tumors (large) and lymphocytes (small cells), and CD45stroma. CD45 cells were further defined as GP38+CD31 CAFs and GP38CD31+ BECs. CD73 expression in each cellular subset in the TME was examined (red histogram) as compared with the isotype control for each population (gray). b Relative percentage of each cellular subset within the TME determined via FACS was summarized. n = 6. c IF staining was employed to examine CD73+ cell (red) bio-distribution in correlation with ER-TR7+ (green) fibroblastic stroma and DAPI nuclear counterstain (blue). Co-localization of CD73high and ER-TR7+ cells was illustrated via merging the images. d The relative area occupied by CD3+ T, CD11b+ myeloid cells, and ER-TR7+ CAFs (red) in the EG7 TME was determined via a computer-assisted software following masking it to white/gray signals and calculated as the percentage of total area. e CD11b+, CD3+ cells, and CAFs were purified from the EG7 TME via FACSort. Their capacity for ADO generation within 2 h in the presence of 200 μM AMP was compared. f Purified CD8 T cells were activated by α-CD3/α-CD28 beads in CAF-conditioned medium (CAF-CM), pre-incubated with or without 200 μM AMP. Changes in the cell surface expression of CD69 and CD25 were examined and compared with the 100 μM ADO control via FACS 15 h post-activation. The viable CD69+CD25+CD8+ T cells were calculated and summarized to the right. Error bars depict mean ± SEM. p values were determined via two-tail unpaired Student’s t-test. All experiments were repeated at least two times. Source data are provided in the Source Data file.

Using FACSort-purified CAFs (Supplementary Fig. 2e), CD3+ T, and CD11b+ myeloid cells from the EG7 TME, we compared their CD73 bioactivity as the capacity of ADO generation via an HPLC-based quantification assay (Supplementary Fig. 2f). We added 200 μM AMP to the CAF culture because early studies indicated that ADO concentrations in the TME could reach 50–100 μM29,30. EG7-CAFs generated close to 100 μM ADO within 4 h (Fig. 2e), which could be inhibited by a CD73 inhibitor, adenosine 5′-(α,β-methylene) diphosphate (APCP) (Supplementary Fig. 2g). In contrast, the same number of purified CD11b+ or CD3+ cells from the same TME generated < 5 μM ADO (Fig. 2e). Moreover, the CAF culture medium in the presence of AMP (AMP-CAF-CM), but not in the absence of AMP (CAF-CM), markedly inhibited T cell activation and proliferation similar to that induced by 100 μM ADO (Fig. 2f, Supplementary Fig. 2h). Together, our results confirm that CD73 on EG7-CAFs plays a dominant role in rapid ADO generation and immunosuppression.

EG7 and human CRC CAFs share similar transcriptome profiles

The dynamic and mutualistic interactions between stroma and tumors in the TME shape the immune landscape and modulate CAF function and phenotype17. Despite the differences in tumor type and species between EG7-CAFs and human CRC-CAFs, we postulated that they share many similar cellular and molecular characteristics besides the CD73hi phenotype and, thus, compared their transcriptome profiles. First, comparative high throughput RNA-sequencing (seq) analysis of purified EG7-CAFs and the early passage murine MSCs, which are thought to be precursors for some CAFs16,20,31 and used as the control for normal mesenchymal cells. With a two-fold difference and a significance of p < 0.01 from 11,839 genes, 1584 differentially expressed genes (DEGs) between CAFs and MSCs were identified (Fig. 3a). These DEGs were pertinent to various pathways, including response to stimulus, metabolism, cancer pathways, ECM, and cell cycle regulation (Fig. 3a and Supplementary Fig. 3a). Gene set enrichment analysis (GSEA) elucidated that genes associated with cytokine–cytokine receptor signaling and ECM were highly enriched in EG7-CAFs (Fig. 3b), consistent with their immune regulatory function and involvement in tissue remodeling. Further analysis of the 417 genes upregulated as response to stimulus via KEGG pathway grouped them into pathways in cancer, ECM, cytokine–cytokine receptor interaction, purine metabolism, etc. (Supplementary Fig. 3b). As expected, cytokine/chemokine and signaling molecules, including various interleukins (IL), IL-receptors, downstream transcription factors, Ccls, Cxcls, Tgfs, Jaks, Stats, and Socs3, were highly elevated in CAFs (Fig. 3c). Likewise, genes associated with ECM, hypoxia, and purine metabolism, such as Cols, Mmps, Hif1α, Epas1 (Hif2α), Nt5e (Cd73), and Entpd2 (Cd39l1), were highly elevated in CAFs compared with MSCs (Fig. 3d–f). Notably, common markers used for defining CAFs, including Pdgfra, Pdgfrb (Fig. 3c), Acta2, Des (Fig. 3d), Fap, Postn, and Thy1 (Fig. 3e), were all expressed at higher levels in CAFs than in MSCs. Collectively, our results clearly support the notion that CAFs are transcriptionally different from MSCs in various pathways and biological processes associated with immune modulation, inflammation, hypoxia, and activation of oncogenic pathways.

Fig. 3: EG7 and human CRC CAFs share similar transcriptome profiles.
figure3

a Comparative expression profile of CAFs and MSCs was analyzed via RNA sequencing. The volcano plot illustrates genes that were significantly upregulated (995, red) and downregulated (589, blue) adjusted for fold change > 2 and p < 0.01 with representative genes associated with specific pathways. b Gene sets specifically enriched among the differentially expressed genes in CAFs were analyzed via gene set enrichment analysis (GSEA). cf The 417 genes categorized in “response to stimulus” were further analyzed for enrichment in KEGG pathways. Representative heatmaps of RNA sequencing data with genes significantly up-regulated in CAFs according to specific pathways were shown from three biological repeats, each extracted from at least five pooled tumor-bearing mice. g Gene set enrichment analysis (GSEA) of differentially expressed genes in human CRC-CAFs compared with paired tumor cells (GSE39396) identified highly enriched genes in pathways related to cytokine–cytokine interaction and ECM receptor interaction. h The gene expression profile heatmap shows differentially expressed genes in paired human CRC tumors, TILs, and CAFs (GSE39396) associated with pathways highly enriched in CRC-CAFs. The list on the right showed a selective representative shortlist of significantly up-regulated genes in CAFs, most of which are similar to those identified in EG7-CAFs. Source data are provided in the Source Data file.

We next analyzed GSE39396 transcriptome dataset of the paired CRC-CAFs, TILs, and tumors. Considering higher individual variations among clinical specimens, we used a 1.5-fold difference with a significance of p < 0.01 and identified 2927 DEGs that expressed at higher levels in CRC-CAFs than in tumors and TILs. Similar to EG7-CAFs, GSEA demonstrated highly enriched gene expression associated with cytokine–cytokine receptors and ECM in CRC-CAFs (Fig. 3g). KEGG analysis also categorized these DEGs into pathways similar to those of EG7-CAFs (Supplementary Fig. 3c). Remarkably, many of the DEGs identified in human CRC-CAFs (Fig. 3h) mirror those in EG7-CAFs (Fig. 3c–f). Together, this comparative transcriptome profiling confirms common characteristics at the molecular level shared between murine and human CAFs from different TME, supporting the clinical relevance of our EG7-CAF as a model system for mechanistic investigation of molecular pathways and therapeutic interventions targeting CAF-CD73-dependent immune suppression in the TME.

CD73 on non-hematopoietic cells promotes tumor progression

We first evaluated the impacts of host CD73 activity on tumor growth by comparing EG7 progression in Cd73null and WT mice. As reported previously12,13, despite their similar tumor establishment during the first week of tumor inoculation (Fig. 4a), EG7 progression in Cd73null mice was hindered during the second week, when tumors reached ~70–100 mm2, followed by regression and elimination (Fig. 4a). In contrast, EG7 in WT mice progressed rapidly and required euthanasia by day 15 (Fig. 4a). Examination of the EG7 tumors established in Cd73null and WT mice for 9 days with similar size demonstrated their comparable CAF abundancy, distribution, and phenotype, except for CD73 expression (Fig. 4b and Supplementary Fig. 4a). Consistent with the observed EG7 regression, CD8+ cells and IFN-γ producing effectors, as well as the CD11c+ myeloid/dendritic cells, increased significantly in the TME of Cd73null mice compared with those of the WT counterparts (Fig. 4c, Supplementary Fig. 4b).

Fig. 4: Cd73 inactivation in the non-hematopoietic compartment hinders tumor progression causing tumor regression.
figure4

a C57BL/6 WT and Cd73null mice received 1 × 106 EG7 tumors s.c. were monitored for tumor progression every other day. Representative images illustrate the tumor size in WT and Cd73null mice at 15 days post-inoculation. b At 9 days post-EG7 inoculation, tumors were collected from WT and Cd73null mice for analysis of EG7-CAF percentage and phenotype. c The percentage of tumor infiltrating CD8+ T cells and IFN-γ+ effectors in the EG7 TME of WT and Cd73null mice were analyzed, summarized, and shown to the right. d Schematic diagram shows reciprocal BMT strategy between WT C57BL/6 (GFP-Tg) and Cd73null mice. e Two months post-BMT, EG7 tumors were established s.c. in these BMT mice and tumor progression was examined every other day. f Representative FACS plots (left) and summary (right) of tumor-infiltrating CD8+ T cells in the BMT mice are presented. g The representative histograms show CD73 expression (red line) compared with isotype control (gray) in CAFs and T cells of the BMT mice. h EG7-CAFs from WT and Cd73null mice were purified via FACSort. Their capacity and kinetics for ADO conversion from 200 μM AMP was determined. i The capacity of WT and Cd73null CAF-conditioned medium in the absence (CAF-CM) or presence of 200 μM AMP (AMP-CAF-CM) for inhibiting T cell proliferation as CFSE dilution was examined. Data depict mean ± SEM. Student’s t-test. n = 5. Source data are provided in the Source Data file.

To verify the contribution of CAF-CD73, we performed reciprocal bone marrow transplantations (BMTs) by transferring BM from WT or Cd73null mice to lethally irradiated GFP-transgenic mice (GFP-Tg) and BM from GFP-Tg or Cd73null mice to irradiated Cd73null mice (Fig. 4d) followed by EG7 inoculation 2 months later. As expected, EG7 progressed rapidly in WT mice that received WT BM (Fig. 4e, WT → WT), but slightly delayed in WT mice that received Cd73null BM (Fig. 4e, Cd73null → WT). Strikingly, Cd73null mice that received either WT or Cd73null BM (Fig. 4e, WT → Cd73null and Cd73null → Cd73null) experienced complete tumor regression resembling un-manipulated Cd73null mice (Fig. 4a). Similarly, the tumor regression in Cd73null BMT mice was associated with a marked increase in CD8+ cells and IFN-γ-producing effectors (Fig. 4f). FACS analysis confirmed that CD73 expression on CAFs matched the recipient genotype, while CD73 expression on T cells agreed with their donor genotype (Fig. 4g). Functionally, Cd73null CAFs were unable to generate ADO, confirming inactivated enzymatic activity (Fig. 4h) and inability to inhibit T cell activation and proliferation (Fig. 4i and Supplementary Fig. 4c). Therefore, Cd73 inactivation in the non-hematopoietic compartment in the EG7 TME, predominately CAFs, leads to enhanced antitumor immunity and consequential tumor elimination.

CAF-CD73 is dynamically regulated via the ADO-A2B pathway

During tumor progression, cancers and other cellular constituents in the TME communicate dynamically and multidimensionally to shape the immunosuppressive landscape. However, it is largely unexplored when/how CAF-network is established and how CD73 activity is regulated. We analyzed EG7 tumors of various sizes and found that CAFs were sparse in small tumors (<50 mm2), covering < 5% of the area and comprising ~0.8% cellularity (Fig. 5a, b). As tumors progressed, CAFs transiently expanded to ~10% of the area and ~1.7% cellularity (medium-size, 50–130 mm2), and eventually formed a well-connected dense network that occupied ~30% of the area and ~3.4% cellularity in large tumors (>150 mm2) (Fig. 5a, b). Notably, CAF-CD73 levels increased rapidly during tumor progression from about 20% CAFs being CD73+ in small tumors to up to 80% CD73+ in large tumors (Fig. 5c and Supplementary Fig. 5a). Interestingly, a progressive increase in tumor hypoxia and necrosis/apoptosis during EG7 progression was observed (Supplementary Fig. 5b), agreeing with previous documentations of tumor growth-associated hypoxia, localized cell death, and activation of multiple pathways32,33.

Fig. 5: CAF-CD73 expression is dynamically upregulated via the ADO-A2B pathway.
figure5

a The relative abundancy and distribution of CAFs in EG7 tumors of various sizes were evaluated via ER-TR7 (green) staining using a computer-assisted software, MetaMorph. Data depict mean ± SEM. b, c The CAF abundancy and CAF-CD73 levels in EG7 of various sizes were analyzed via FACS. d EG7-CAFs were treated with 100 μM ADO for 6 and 24 h and their Nt5e (Cd73) expression was determined via quantitative real-time RT-PCR. e EG7-CAFs were treated with 100 μM ADO in the absence or presence of A2A or A2B antagonists, ZM241385 or PSB1115, respectively. Relative CD73 expression on CAFs was determined via FACS. f EG7 tumor-bearing WT mice were treated with daily i.p. injection of 1 mg kg−1 body weight of PSB1115 or vehicle (DMSO) as a control. CD73 expression on CAFs were examined via FACS. g WT and A2bnull mice were inoculated with EG7 tumors and their CAF-CD73 expression from tumors of similar sizes was compared. h EG7 tumor-bearing WT mice were treated with daily i.p. injection of 1 mg kg−1 body weight of PSB1115 or vehicle starting from 5-day post-tumor inoculation followed with i.t. injections of 100 μl of 20 μM nutlin at days 6 and 8. i EG7 tumor-bearing A2bnull mice were treated with i.t. injections of 100 μl of 20 μM nutlin at days 6 and 8 post-tumor establishment. CD73 expression on CAFs from WT h and A2bnull i mice were analyzed via FACS and compared to those without nultin-treatment (n = 5). Error bars depict mean ± SEM. p values were determined via two-tail unpaired Student’s t-test a, di. Linear regression analysis was performed to determine the correlation between the tumor size and CAF% or CD73+CAF% in b, c, respectively. All experiments were repeated at least two times. Source data are provided in the Source Data file.

To delineate the molecular mechanism by which CAF-CD73 is upregulated, we first cultured EG7-CAFs and MSCs in hypoxia chambers (1% O2) and found that neither Nt5e mRNA nor surface CD73 expression was elevated despite their marked upregulation of hypoxia-associated genes, hypoxia-inducible factor 1 alpha (Hif1α) and Vegfa (Supplementary Fig. 5c, d). Thus, unlike the early report of HIF-1α-dependent CD73 upregulation in intestinal epithelium34, CD73 expression in fibroblastic stroma is regulated via other mechanisms. Because tumor hypoxia-induced cell death leads to elevated ADO in the TME29,30,35, we then cultured CAFs in the presence of ADO, which markedly elevated Nt5e expression within 24 h (Fig. 5d). Adenosinergic receptors of various subtypes are constitutively, but differentially expressed in different tissues3,36,37. Our RNA-seq results suggested that Adora2a (A2a) and Adora2b (A2b) are the major subtypes expressed in the fibroblastic stroma. Comparative analysis of their expression in CAFs, MSCs, and T cells via real-time RT-PCR revealed that T cells predominately expressed A2a with a barely detectable A2b, whereas CAFs and MSCs preferentially expressed 10–50 fold higher A2b than A2a (Supplementary Fig. 5e). Treatment of EG7-CAFs with ADO in the presence of either A2A or A2B antagonist, ZM241385 (ZM) or PSB1115 (PSB), respectively, demonstrated that A2B but not A2A antagonist prevented ADO-induced CD73 upregulation (Fig. 5e). Furthermore, in vivo treatment of EG7-bearing WT mice with daily PSB1115 injection markedly suppressed CD73+ CAFs by about 50%, without affecting CAF abundancy, compared to those in vehicle-treated control (Fig. 5f, Supplementary Fig. 5f). Notably, the effects of PSB1115 on CAF-CD73 expression were cell-type specific because CD73 levels in CD4 T cells in the same TME were unaffected (Supplementary Fig. 5g). Consistent with these observation, CD73 levels on EG7-CAFs from A2bnull mice were significantly lower than those from their WT counterparts of comparable tumor size (Fig. 5g).

Therapy-induced cell death and tissue damage cause substantial elevation of eADO level associated with massive ATP release and conversion38,39, which we speculated to account for one of the mechanisms by which chemotherapy and radiotherapy activate CAFs via activating the ADO-CD73 axis to enhance their pro-tumor and immunosuppressive function40,41,42. Analysis of a published human CRC dataset (GSE 15781) consisting of patients with or without radiotherapy prior to surgery indicated that NT5E levels in the TME of patients receiving radiotherapy were significantly higher than those without radiation (Supplementary Fig. 5h). Previously, we showed that intratumoral (i.t.) injection of a p53 activator nutlin-3a (nutlin) to EG7 tumors induced localized cell death within the TME43. Here, we demonstrated that nutlin treatment robustly augmented CAF-CD73 upregulation, which could be prevented by PSB treatment during the period of nutlin injections (Fig. 5h). Likewise, in A2bnull mice, this nultin-induced CD73 upregulation on EG7-CAFs was alleviated (Fig. 5i), which agreed with the observed failure of ADO to induce CD73 upregulation on A2bnull CAFs in the presence of ADO (supplementary Fig. 5i). Altogether, these results suggest that therapy-associated ADO elevation is a direct mediator of CAF-CD73 upregulation via activation of A2B, which initiates a feedforward circuit to amplify the CD73-ADO axis in the TME. A2B antagonist PSB1115 or A2b inactivation alleviates ADO-mediated CAF-CD73 upregulation, which potentially unleashes the CAF-CD73 checkpoint and enhances antitumor immunity.

Anti-CD73 with A2A and A2B antagonists inhibits EG7 growth

Currently, anti-CD73 blockade, either as a monotherapy or combination with A2A antagonist44, is being tested in clinical trials3. Based on our observed preferential A2B expression in CAFs and the A2B-dependent CD73 amplification circuit, we hypothesized that incorporating the A2B antagonist therapeutically further inhibits the CAF-CD73 immune checkpoint. In EG7-bearing mice, A2A antagonist ZM241385, A2B antagonist PSB1115, or CD73-neutralization individually resulted in a similar modest but statistically significant suppression of EG7 tumor progression (Fig. 6a, b) with marked increases in total TIL-CD8 cells and IFN-γ-producing CTLs compared to those in iso-type control-treated mice (Fig. 6c). Notably, ZM243185 induced the most profound increases in immune effectors (Fig. 6c), whereas PSB1115 treatment markedly inhibited CD73 upregulation in CAFs (Fig. 6d), and CD73-neutralization completely masked CD73 staining on both CAFs and CD4 cells without affecting CAF abundancy (Supplementary Fig. 6a, b). Combinatorial of anti-CD73 together with PSB1115 further improved tumor control and inclusion of A2A and A2B antagonists with CD73-neutralization markedly restrained tumor progression leading to complete tumor elimination in some mice (Fig. 6e). Interestingly, combination of ZM243185 and PSB1115 without anti-CD73 significantly improved tumor control during early phase of the treatment similar to that seen in the three-regimen combination, but was less effective in the later phase of the treatment (Fig. 6e). Consistent with the effective tumor control, the effector frequencies were highest in the ZM243185 + PSB1115 and three-regimen combination groups with ~3-fold increase in TIL-CD8 and CTLs (Fig. 6f). Furthermore, the three-regimen combination imposed a better suppression of CAF expansion and CD73 expression than the ZM243185 and PSB1115 combination (Fig. 6g and Supplementary Fig. 6c), agreeing with the better long-term tumor control in the three-regimen combination group (Fig. 6e). Together, these results demonstrate that blocking the non-redundant functions of A2A, A2B, and CD73 in the TME of CD73 tumors are crucial for maximal reversal of the immune suppression by alleviating the A2B-CD73 feedforward circuit in CAFs that enforces the CD73-ADO immune checkpoint.

Fig. 6: CD73 neutralization in combination with A2A and A2B antagonists leads to significant EG7 tumor regression.
figure6

a Schematic illustration of timeline and treatments of EG7-bearing WT mice with daily i.p. injection of 1 mg kg−1 body weight of A2A antagonist ZM241385 or A2B antagonist PSB1115 with or without anti-CD73 treatment. b Tumor progression was examined every day. c The percentage of TIL-CD8 T cells in the EG7 TME and IFN-g-producing CTLs were determined via FACS and summarized. d The percentage of CD73hi/+ CAFs in the TME following different treatments were analyzed via FACS. e EG7-bearing mice were treated with daily i.p. injection of combined ZM and PSB with or without anti-CD73. Tumor progression was monitored every day. f The percentage of TIL-CD8 T cells and IFN-g-producing CTLs in the EG7 TME were analyzed via FACS. g The percentage of CD73hi/+ CAFs in the TME of various treated groups were analyzed via FACS. b, e p values were determined via multiple t-tests where the tumor sizes at each time point were compared. c, d, f, g Error bars depict mean ± SEM. p values were determined via two-tailed unpaired Student’s t-test. All experiments were repeated at least two times. Source data are provided in the Source Data file.

A2B blockade in the CAF-poor MC38 fails to suppress CAF-CD73

We next examined whether these mono- or combinatorial regimens targeting the CD73 and adenosinergic pathways were effective for treating MC38-CRC, which expresses high levels of CD73 with low CAF abundancy (Supplementary Fig. 2). CD73-neutralization, ZM241385, or PSB1115 alone caused a similar and significant delay in MC38 progression (Fig. 7a). Notably, neither ZM241385 nor PSB1115 suppressed CAF-CD73 levels on MC38-CAFs despite a marked suppression of CD73 on MC38 by PSB1115 (Fig. 7b, c). CD73-neutralization alone effectively blocked CD73 detection on both MC38-CAFs and tumors (Fig. 7b, c). Surprisingly, combination of ZM241385 and PSB1115 either in the absence or presence of anti-CD73 did not impose synergistic or additive effects on controlling MC38 progression beyond those observed in monotherapies (Fig. 7d), neither did they effectively suppress CD73 upregulation on MC38-CAFs (Fig. 7e) nor unaltered MC38-CAF abundancy (Supplementary Fig. 7a). Interestingly, CD73-neutralization in ZM241385 and PSB1115-treated mice inhibited CD73 detection on MC38 tumors (Fig. 7f), implying that the accessibility and effects of these therapeutic agents to MC38-CAFs are potentially limited and that the observed control of MC38 progression is likely contributed directly by the agent-mediated tumor killing (Supplementary Fig. 7b) and/or modification of TILs, instead of the CAF-CD73 modification demonstrated in the EG7 TME.

Fig. 7: Adenosinergic antagonism is ineffective in modulating CAF-CD73 expression in the CAF-poor MC38 tumors.
figure7

a MC38 tumor-bearing mice were treated with daily i.p. injection of A2A antagonist ZM241385 or A2B antagonist PSB1115 or anti-CD73 every other day. Tumor progression was examined every day. b, c The percentage of CD73hi/+ CAFs (b) and MC38 tumors (c) in the TME following different treatments were analyzed via FACS. d MC38 tumor progression in WT mice receiving combination treatment of ZM243185 and PSB1115 in the absence or presence of anti-CD73 was examined every day. e, f The percentage of CD73hi/+ CAFs (e) and MC38 tumors (f) in the TME following different treatments were analyzed via FACS. g Representative images of IHC staining of CD73 (red), α-SMA (green), and vimentin (white) revealed their levels and distribution within the MC38 TME. The percentage of a-SMA+ signal covering the entire TME was determined via the Inform software and presented to the left. h MC38 tumor established in WT mice were collected at different sizes for FACS analysis. The relative CAF abundancy and CD73hi/+ CAFs within the MC38 TME in association with tumor size were evaluated via linear regression. i MC38 tumors were cultured with 100 μM ADO in the absence of presence of 10 mM ZM241385 or PSB115 for 48 h. Their Cd73 mRNA levels relative to that of b-actin was analyzed via real-time RT-PCR. j Representative images of IHC staining of CD73 (red), α-SMA (green), apoptotic cells (cleaved caspase-3+, cyan) and vimentin (white) levels and their distribution in the MC38 TME treated with or without ZM241385 and PSB115. a, d p values were determined via multiple t-tests where the tumor sizes at each time point were compared. b, c, e, f, g, i Error bars depict mean ± SEM. p values were determined via two-tailed unpaired Student’s t-test. g, h Scale bars, 50 μm. All experiments were repeated at least two times. Source data are provided in the Source Data file.

Histologically, MC38 exhibited spindle-shaped mesenchymal-like phenotype (Supplementary Fig. 7c). Transcriptionally, MC38 expressed high levels of FB/mesenchymal-associated molecules, suggesting an epithelial to mesenchymal transition (EMT) phenotype (Supplementary Fig. 7d), which differed markedly from that of typical human CRC-adenocarcinomas (CRC-Tu, Supplementary Fig. 7e). Comparative analysis of FACSort-purified MC38-CAFs (Supplementary Fig. 7f) revealed that they expressed higher levels of Cd73 mRNA than that of MC38 tumors and EG7-CAFs (Supplementary Fig. 7g). Furthermore, despite a moderate expression in MC38-tumors, α-Sma mRNA in MC38-CAFs was a 1000-fold higher (Supplementary Fig. 7h), which allowed for the α-SMA as a marker to distinguish MC38-CAFs from MC38E (Fig. 7g). Strikingly, IHC analysis revealed that MC38-CAFs were scattered sparsely, only covering ~2% of the TME (Fig. 7g) unlike the abundant/sophisticated CAF-networks in the EG7-TME and those in clinical CRC specimens (Fig. 1a). Furthermore, the frequency of MC38-CAFs remained unchanged although the relative percentage of CD73+/hi CAFs elevated gradually during tumor progression (Fig. 7h). In vitro and in vivo studies revealed that MC38 was more susceptible than MSCs to ZM241385-induced cell death (Supplementary Fig. 7i), which likely triggered the ADO-dependent CD73 upregulation in the remaining MC38 cells and adjacent MC38-CAFs (Fig. 7i, j). Consistent with their mesenchymal phenotype, PSB1115 suppressed ADO-induced CD73 upregulation in MC38 cells (Fig. 7i) with modest toxicity (Supplementary Fig. 7j). Together, these results support our hypothesis that the therapeutic efficacy of mono- or combination therapies in MC38 tumors is largely resulted by adenosinergic antagonist-induced tumor death (Fig. 7j). The sparse presence of MC38-CAFs limits their direct interaction with TILs within the TME.

The A2B blockade-induced tumor regression is CAF-dependent

To define whether the high CD73 expression in MC38 and/or their limited CAF distribution are the major barriers of effective combinatorial therapy, we generated MC38-Cd73KO single cell clones using the CRISPR/Cas9-directed gene knockout technology and FACSort based on the RFP-reporter expression. We used one clone, F2C11 (called MC38Cd73KO) for this study following the confirmation of Cd73 inactivation/deletion in two alleles via surface staining, mRNA expression, and genomic DNA PCR flanking the target sequences at the exon-2 of Cd73 gene (Supplementary Fig. 8a–c). Despite a comparable growth rate in culture between the MC38Cd73KO and MC38 cells (Supplementary Fig. 8d), MC38Cd73KO tumor progression in WT mice was significantly delayed compared to unmodified MC38 tumors and MC38 modified to express RFP (MC38-RFP) (Fig. 8a). The delayed MC38Cd73KO progression was associated with a marked increase in tumor-infiltrating CD8 cells (Fig. 8b) and elevated IFN-γ production (Fig. 8c) without marked changes in either CAF abundancy or CD73hi/+ CAFs (Supplementary Fig. 8e). Importantly, CD73-neutralization further suppressed MC38Cd73KO progression leading to their elimination in about 50% of the mice, suggesting the preservation of CD73-checkpoint during MC38Cd73KO tumor progression (Fig. 8a).

Fig. 8: The synergistic effects of combined adenosinergic antagonism and CD73 blockade on tumor control is CAF-dependent.
figure8

a The progression of MC38Cd73KO and MC38-RFP in WT mice was compared the unmodified MC38 tumors. A group of MC38Cd73KO-bearing mice also received i.p. injection of anti-CD73 every other day. Tumor progression was examined every day. b The percentage of TIL-CD8 T cells and c IFN-γ-producing CTLs in the TME of MC38 and MC38Cd73KO were determined via FACS and summarized. dg The progression of MC38Cd73KO tumors established in WT mice with MSCs co-inoculation with or without anti-CD73 or PSB1115 treatment was examined every day d. e CD73+ (red) and α-SMA+ (green) cells and their distribution within the TME of MC38Cd73KO tumors without or with MSC co-inoculation were analyzed and quantified via IHC. f, g The percentage of CD73hi/+ CAFs (f) and TIL-CD8 T cells (g) in the TME MC38Cd73KO tumors co-inoculated with MSCs following different treatments were determined via FACS and summarized. hj The progression of MC38Cd73KO tumors co-inoculated with MSC and treated with ZM243185 and PSB1115 combination in the absence or presence of anti-CD73 was examined every day g. i, j The percentage of CD73hi/+ CAFs i and TIL-CD8 T cells j in the TME MC38Cd73KO tumors with MSC co-inoculation following different treatments were determined via FACS and summarized. a, d, g p values were determined via multiple t-tests where the tumor sizes at each time point were compared. b, c, e, f, i, j Error bars depict mean ± SEM. p values were determined via two-tailed unpaired Student’s t-test. All experiments were repeated at least two times. Source data are provided as a Source Data file.

Co-inoculation of MC38Cd73KO with MSCs greatly accelerated tumor progression with a marked increase in CAF (α-SMA+) abundancy (Fig. 8d, e, Supplementary Fig. 8g, h), which marginally impacted TIL-CD8 cells (Fig. 8g, Supplementary Fig. 8g, h). CD73-neutralization or A2B antagonist PSB1115 significantly suppressed MSC/CAF-assisted MC38Cd73KO progression by inhibiting CAF-CD73 upregulation and enhancing TIL-CD8 cells (Fig. 8f, g) without marked alterations in CAF abundancy (Supplementary Fig. 8i). Combinatorial regimen of ZM241385 and PSB1115 markedly suppressed MSC/CAF-assisted MC38Cd73KO progression, which was further enhanced by CD73-neutralization (Fig. 8h) with significant suppression of CAF-CD73hi/+ population and enhanced TIL-CD8 cells (Fig. 8i, j). Interestingly, ZM241385 and PSB1115 combination in the absence of anti-CD73 resulted in a marked reduction of CAFs, but not the frequency of CD73hi/+ CAFs (Fig. 8i, Supplementary Fig. 8j). Noticeably, neither combinatorial regimens impacted the frequency of IFN-γ+ CD8 T cells (Supplementary Fig. 8k). Together, in this modified MC38-CRC model, where tumor Cd73 is inactivated with adequate presences of CAFs, the synergistic effects of adenosinergic antagonism and CD73-blockade was recapitulated as those seen in the EG7 tumor model. These results suggest that the abundancy and distribution of CAFs are essential for effective therapy of combined adenosinergic antagonism and CD73-neutralization.

Discussion

Immune checkpoint inhibitors targeting the PD-1/PD-L1 or CTLA-4 pathway to unleash tumor-mediated immunosuppression remarkably improved clinical outcomes for some patients with various types of cancer45,46. Here, we elucidate that the highly elevated CD73 activity in CAFs by converting eATP to eADO and through the ADO-CD73 pathways in CAF-network represents another previously unidentified, non-redundant immune checkpoint. Our results substantiate the pivotal roles of CAFs in enforcing immunosuppression and promoting tumor progression, and shed light onto one of the mechanisms of action, which is by far not fully explicated15,17,20,47,48,49,50,51,52. Mechanistically, elevated ADO in the TME upregulates CD73 on CAFs via A2B-mediated pathway, thereby inciting the ADO-A2B-CD73 feedforward circuitry (Fig. 9), which further augments immunosuppression by activating the non-redundant ADO-A2A pathway in immune cells to inhibit immune activation (Fig. 9). Importantly, our demonstrated A2B-mediated CD73 upregulation in CAFs and mesenchymal-like tumors provides not only a mechanistic explanation for previously reported therapy or stress-induced CD73 upregulation10,26,42,44,53,54, but also informative practical considerations for inhibiting immune checkpoint with minimal toxicity. Pathological or therapeutic-associated tissue damage/cell death may rapidly elevate eADO level up to 100 μM29,55, which strongly activates the A2B pathway for CD73 upregulation regardless of A2A blockade10,42,44. In this context, A2B blockade with the CD73-neutralization to collaboratively alleviate the prevalent CD73-ADO checkpoint in CAF leads to improvement in clinical outcomes. Therapeutically, our results with two murine tumor models underscore the effectiveness of simultaneous inhibition of the non-redundant suppressive pathway of A2A and A2B-dependent CD73-ADO immune checkpoint for improving antitumor immunity.

Fig. 9
figure9

A schematic illustration of the proposed mechanism of pathological and therapy-induced CAF-CD73 upregulation enforcing the immune checkpoint in the TME.

Clinical association between elevated CD73 expression and poor prognosis has been well documented in many tumor types7,9,26,27,28,49,56. The contribution of CD73 activity in Tregs and vasculature to this overall CD73-mediated immunosuppression has been well demonstrated24,45,46,47. Nevertheless, the contribution of CD73 activity in CAFs, which are prominent stroma population in the TME associated with poor survival for many tumor types15,16,17,18,23,50, remains poorly defined. Our comparative studies, using the murine CD73-EG7 tumor model, modified MC38dD73KO-CRC model, and correlative analyses of human CRC specimens and published datasets, clearly establish that the CD73hi-CAF identity represents a general attribute and a shared immunosuppressive mechanism among different tumor types and species. Our data thus support the previous work demonstrating that CD73 on CAFs promotes tumor immune escape in a mouse model of ovarian cancer9. Furthermore, our results demonstrate an association between elevated CD73 levels in the TME and CAF abundancy, poor clinical outcomes in CRC patients, and accelerated tumor progression in mice models.

Particularly, the synergistic effects of combinatorial adenosinergic antagonism and CD73-neutralization regimen largely depends on the abundant CAF distribution within the TME. Besides the sparse CAF distribution in the MC38 TME, the mesenchymal-like EMT characteristics of MC38, unlike the typical CD73 CRC-adenocarcinomas, further complicated the therapeutic outcomes via: (1) a similar response to ADO-A2B-mediated CD73 upregulation to that observed in CAFs, which is potentially overwhelmingly active and counter-productive, especially at the sites of therapy-induced tumor death, contributing to the ineffective suppression of the overall CD73 levels/activity within the TME, and (2) an equally if not more detrimental attribute of the high susceptibility of MC38 to ZM243185-induced rapid and massive cell death, which triggers additional toxicity to the TILs and CAFs besides enforcing the ADO-A2B-CD73 circuitry (Fig. 7 and Supplementary Fig. 7). Therefore, for tumors that are highly sensitive to adenosinergic antagonism for apoptosis-induction and/or ADO-induced CD73 upregulation, A2A and A2B antagonists should be used with caution, whereas improving the dose and delivery route of anti-CD73 regimen will be safer. Undoubtedly, initial assessment of clinical patients/TME with specific considerations of the CAF abundancy, potential effects of ADO on tumor-CD73 levels, and their sensitivity to adenosinergic antagonist-induced cell death will further improve clinical outcomes and limiting toxicity for personalized immunotherapy and other therapeutic strategies to effectively inhibit CD73 checkpoint57,58,59.

In summary, this study clearly and robustly illustrates one of previously unidentified immunosuppressive functions of CAFs via high CD73 expression and bioactivity. This CAF-CD73hi status is dynamically regulated and enforced during tumor progression and therapy via CAF/tissue-specific A2B pathway. Therapeutically, simultaneous blockade of the non-redundant CAF-A2B-CD73 circuit and ADO-A2A-dependent inhibition of immune activation will be vital to improve the currently proposed/on-going tests of A2A and/or CD73-neutralization clinical trials, as well as other activate therapies that induce massive cell death10,26,42,60,61, to alleviate the CAF-CD73-mediated immune checkpoint for ultimate and durable tumor control.

Methods

Mice, cell lines, and clinical specimens

C57BL/6 mice were purchased from Charles River (Wilmington, MA). CD73null (B6.129S1-Nt5etm1Lft/J), GFP-Tg (C57BL/6-Tg(UBC-GFP)30Scha/J), and A2Bnull (B6.129P2-Adora2btm1Till/J) mice were obtained from the Jackson Laboratory (Bar Harbor, ME). All mice were maintained under specific pathogen-free conditions in the animal facility of Augusta University following protocols approved by the Augusta University Institutional Animal Care and Use Committee. Ova-expressing E.G7-OVA (EG7) cell line was purchased from ATCC (CRL-2113, Manassas, VA) and murine colorectal cancer cell line, MC-38, was obtained from Kerafast (ENH204-FP, Boston, MA). Early passage MSCs from C57BL/6 background were purchased from Cyagen (MUBMX-01001, Santa Clara, CA). Mycoplasma contamination was periodically tested with the culture medium via the standard PCR-based assay. De-identified FEPE and frozen human colorectal cancer specimens were obtained from Georgia Cancer Center Biorepository following protocols approved by the Augusta University Institutional Review Board committee.

Antibodies and reagents

Antibody staining for flow cytometry analysis of relevant markers was performed with 1 × 106 cells in 100 μl staining buffer at the Ab concentration of 2 μg ml−1: anti-CD4 (RM4-5), anti-CD8α (53-6.7), anti-CD11b (M1/70), anti-CD25 (PC61), anti-CD31 (MEC13.3), anti-CD45.2 (104), anti-CD69 (H1.2F3), and anti-CD90.2 (53-2.1) were from BD Biosciences (San Jose, CA); anti-CD73 (TY/11.8), anti-IFN-γ (XMG1.2), and 7-AAD (7-Aminoactinomycin D) were from eBioscience (San Diego, CA); anti-mouse Gp38 (8.1.1) and Zombie Violet Fixable Viability Dye (#423113) were from Biolegend (San Diego, CA). Anti-HIF-1α (D2U3T) was from Cell signaling (Boston, MA); anti-ER-TR7 was from Abcam (Cambridge, MA); Alexa Fluor-conjugated goat secondary Abs were from Life Technologies (Carlsbad, CA). Functional-grade purified anti-CD73 (clone TY/23) and rat IgG2a isotype control (clone 2A3) for in vivo study were obtained from Bio X Cell (West Lebanon, NH). Mouse T-activator CD3/CD28 Dynabeads and CFSE [5(6)-carboxyfluorescein diacetate, succinimidyl ester] were from Life Technologies. Adenosine, AMP, and APCP were from Sigma (St. Louis, MO). Adnosinergic receptor antagonists, PSB1115 and ZM241385, were purchased from Tocris Bioscience (Bristol, UK). LSRII (BD Biosciences) was used for flow cytometry acquisition and data were analyzed using FlowJo (Tree Star Inc., Ashland, OR). The catalog number and concentration of each antibody used in this study is compiled in Supplementary Table 3.

Tumor inoculation and treatment

EG7 and MC38 cells were maintained in DMEM (Invitrogen, Carlsbad, CA) with 10% FBS and 0.4 mg ml−1 G418. Tumor cells in exponential growth phase were collected and injected subcutaneously at 1 × 106 mouse−1 in the right flank of C57BL/6 WT or CD73null mice. Tumors were measured every other day and calculated as: volume = (length × width). For BMT study, C57BL/6 (or GFP-Tg) WT or Cd73null mice were first irradiated with a JL Shepherd (San Fernando, CA) Mark 168 animal irradiator with a Co60 source for 950 cGy. Four hours following irradiation, each mouse received 5 × 106 total bone marrow cells from either C57BL/6 (or GFP-Tg) WT or Cd73null mice via tail vein. Eight weeks following BMT, bone marrow chimerism of >95% donor origin circulating blood cells was confirmed via FACS. Therapeutic interventions, including anti-CD73 or adenosinergic antagonist treatment, were initiated as soon as s.c. inoculated EG7 tumors reached the size of ~20–25 mm2, usually around day 5 post-inoculation, by i.p. injection of 100 μg anti-CD73 or rat IgG2a isotype control every other day or daily i.p. injection of ZM241385 or PSB1115 at 1 mg kg−1 body weight.

CAF purification and culture

EG7 tumor tissues pooled from multiple mice were dissected and minced into small pieces and digested with 0.8 mg ml−1 Dispase, 0.2 mg ml−1 Collagenase P, and 0.1 mg ml−1 DNase I (all from Roche, Basel, Switzerland) at 37 °C for 60 min with shaking. At the end of 60 min digestion, digested tissues were pipetted forcefully to disperse them into single cell suspension. These digested cells were FACSort purified using FACSAria with a 100 μm nozzle (BD Biosciences) as CD45CD11bCD31GP38+ CAFs with a purity of >95%. These fresh CAFs were used for RNA harvesting and RNA-seq analysis. For in vitro CAF culture experiments, the above enzymatically digested cells were plated in 100-mm dishes in DMEM medium containing 10% FBS and non-adherent cells were removed 12 h later. The adherent cells, usually consisting of 30% CD11b+ cells and ~70% CD11bCD45 stromal cells, were subsequently purified by FACsorting as CD45CD11bCD31GP38+ CAFs (>95% purity) or alternatively enriched via a magnetic bead-based negative depletion process using the EasySep mouse CD11b selection kit (Stemcell Technology, Vancouver, Canada) with a modification of adding additional anti-CD45.2 (clone 104) together with anti-CD11b from the EasySep kit to remove potential residual EG7 tumors and other immune cells. This usually resulted in a purity of > 90% CD45CD11bCD31GP38+ CAFs. These purified CAFs were used immediately for in vitro experiments. Early passage (p6) MSCs from Cyagen were expanded for no more than two passages in DMEM medium with 10% FBS before being used for RNA-seq analysis or other experimental treatments as described.

Tissue histology and IF staining

Human CRC Multiplex IHC staining was performed using sections of formalin-fixed paraffin embedded human CRC specimen and reagents in the Opal 7 solid tumor immunology kit (Perkin Elmer, USA) as per manufacturet's instructions. The antibodies used were listed as the following clones with dilutions listed in Supplementary Table 3: anti-α-SMA (1A4), anti-CD3 (SP7), anti-Vimentin (EPR3776), and anti-CD11b (EPR1344) from Abcam (Cambridge, MA), and anti-CD73 (D7F9A) from Cell Signaling (Danvers, MA). Images were acquired by using Vectra 3 quantitative pathology imaging system (Perkin Elmer). The image analysis and calculation of co-localization were performed using Inform software (Perkin Elmer) with 14–20 randomly selected and evenly distributed areas of ~5 × 105 μm2 from each section. The relative percentage of CD73 distribution on CAFs, myeloid, and T cells was calculated against the total CD73+ region in each area, which was set as 100%. Tumor samples were snap frozen in liquid nitrogen. Cryosections were fixed in ice-cold acetone and pre-incubated in blocking solution (1% BSA and 5% goat serum in PBS) for 30 min at room temperature (RT). The primary antibody labeling was performed overnight at 4 °C, followed by a secondary antibody binding for 2 h at RT. Assessment of tumor hypoxia was performed using the HypoxyprobeTM kit (Hypoxyprobe Inc., MA). Specifically, tumor-bearing mice received i.p. injection of pimonidazole HCl in PBS at 60 mg kg−1 90 min before euthanasia. Tumors were immediately excised and snap frozen in liquid nitrogen. Cryosections were fixed in ice-cold acetone and pre-incubated in blocking solution for 30 min at room temperature (RT) and a subsequent incubation with anti-pimonidazole antibody (MAb1, clone 4.3.11.3) at 1.2 μg ml−1 overnight at 4 °C, followed by a secondary antibody binding for 2 h at RT. Images were acquired using Evos (Life Technologies) fluorescent microscope and subsequently resized using Adobe Photoshop CS.

Principle component analysis (PCA) of gene expression

We first defined FB-specific or immune response-associated genes. The 18 FB-specific genes were selected based on highly elevated genes in CRC-CAFs reported by Calon et al. (Nat. Genet. 47, 320–329 (2015)). Most of the 18 selected genes are those commonly used to define CAFs or FBs. The 15 immune response-associated genes were generated from the commonly used immune signaling and function-related genes. The specificity of these two sets of pre-defined genes were further validated by at least two-fold higher expression in purified CRC-CAFs or CRC-TILs, respectively, compared with purified counterparts in the same TME from two published datasets (GSE39396 and GSE39395). The gene expression dataset (GSE39582) of a cohort of 585 human CRC specimens was used for PCA to first extract the NT5ehigh and NT5elow groups as specimens in the top 20% and bottom 20% of NT5e expression levels, respectively. They were subsequently clustered with K-means (K = 4) according to the category of NT5ehigh and NT5elow expression against their average extents of the overall normalized expression of the pre-defined FB-specific genes, which revealed a positive correlation. Likewise, the K-mean clustering was applied to the category of NT5ehigh and NT5elow versus the 15 pre-defined immune response-associated genes established a negative correlation. Finally, the overlapping 106 CRC specimens were generated for plotting the centroid PCA analyses on NT5ehigh and NT5elow against either the expressions of FB-specific genes or that of immune response genes with the successfully separated clusters corresponding to the levels of NT5E expression as shown in Fig. 1.

High performance liquid chromatography (HPLC) assay for adenosine

HPLC was performed using the Prominence UFLC liquid chromatography system (Shimadzu, Toyko, Japan) with a 2.1 × 100 mm Ascentis Express OH5 column (Sigma-Aldrich). Mobile phase A consisted of 10% 10 mM ammonium acetate buffer adjusted to pH 5.5 in 90% acetonitrile. Mobile phase B consisted of 50% acetonitrile. A linear gradient profile from 15% B (5 min) to 100% B (1 min) followed by a 5 min period of 15% B. The column temperature was controlled at 33 °C and UV260 nm was used for adenosine detection. The LC system was controlled and the output signal was monitored by using Shimadzu LC solution software.

CD8+ T cell activation in CAF condition medium

Purified CAFs were seeded in a six-well plate at 1 × 105 well−1. After the overnight culture for CAF attachment, 200 μM AMP was added for 4 h and supernatant harvested as CAF condition medium (CAF-CM). Naïve CD8 T cells were enriched using EasySepTM negative selection kit (Stem Cell Technology). 5 × 105-purified T cells, either CFSE-labeled or unlabeled, in fresh RPMI-1640 medium (10% FBS) were mixed with CAF-CM at 1:1 and activated by α-CD3/CD28 activation beads (Life Technologies). Early T cell activation was analyzed for 6–15 h post-stimulation and T cell proliferation as CFSE dilution was examined 2–3 days post-stimulation.

Analyses of gene expression via RNA-seq and RT-PCR

CAFs were purified from EG7 tumor-bearing mice as described above. Early passage (p6) murine MSCs purchased from Cyagen were cultured in DMEM supplemented with 2 mM of l-glutamine, 3.7 g/l NaHCO3, and 10% FBS for no more than two passages. Total RNA was harvested from purified CAFs and MSCs using Trizol reagent (Thermo Fisher Scientific) followed with Purelink RNA mini kit (Thermo Fisher Scientific). RT was performed with 1 μg of total RNA using random hexamers as primers and Superscript II reverse transcriptase (Life Technologies). Real-time PCR was carried out following standard protocols with primers purchased from Integrated DNA Technologies (Coralville, IA) using a BioRad CFX384 (BioRad Life Science Research, Hercules, CA). Primers used for the amplification of murine Nt5e, Hif1a, vegfa, Adora2a, Adora2b, and β-actin are listed in Supplementary Table 2.

For RNA-seq library preparation, ~200–300 ng Total RNA was used following the Illumina TruSeq stranded mRNA sample preparation guide. After RNA-seq libraries were subjected to quantification process, pooled for cBot amplification and subsequent 50 bp single read sequencing run with Illumina HiSeq 3000 platform. After the sequencing run, demultiplexing with Bcl2fastq2 was employed to generate the fastq file for each sample.

RNA quality assessment, libraries preparation, and RNA sequencing were all performed in the Genome Core of Greehey Children’s Cancer Research Institute, University of Texas Health Science Center at San Antonio. High throughput RNA sequencing reads were mapped to the reference genome (NCBI, UCSC/mm10) using Tophat 2.0.1162 and the relative gene expression was estimated using cufflinks 2.0.263. All RNA-seq data are available at Genes Expression Omnibus (GEO) under the accession number GSE141199. Gene expression differential testing was performed by using cuffdiff 2.0.263. Genes with adjusted p < 0.01 were selected as significantly differentially expressed. GSEA4.0.0 software (Broad Institute) was used for GSEA and KEGG pathway analysis was performed using WEB-based GEne SeT AnaLysis Toolkit (http://www.webgestalt.org/option.php). Heat maps of DEGs were created using MORPHEUS online software.

Human patient sample analysis

Transcriptome datasets of human CRC and breast cancer patient specimens were downloaded from NCBI GEP or the cBio Cancer Genomics Portal website. The transcriptomic profile, expression of NT5E, HIF1A, and EPAS1, gene coexpression network analysis, and Kaplan–Meier curve of patient survival probability were carried out following standard procedures, including the R2: Genomics Analysis and Visualization Platform (http://r2.amc.nl).

CRISPR/Cas9-based Nt5e gene knockout in MC38 tumors

Cd73 CRISPR/Cas9 KO plasmids (Santa Cruz, sc-423919) and Cd73 HDR plasmids (Santa Cruz, sc-423919-HDR) were co-transfected into MC38 tumors using Invitrogen Lipofectamine LTX transfection reagent. Forty-eight hours post-transfection, transfected MC38 cells were first subjected to a 5-day puromycin selection followed by single cell cloning via FACSorting of RFPhigh cells. Following expansion of various MC38Cd73KO clones, their expression of reporter RFP associated with the lost CD73 expression in culture and in vivo were confirmed via FACS analysis. Subsequently, total RNAs and genomic DNA were harvested from these established MC38Cd73KO clones for further confirmation as the molecular levels for their lack of Cd73 mRNA expression and deletions via PCR-based amplification with primers annealing exon 2 region of the CD73 gene, which was suggested by the Santa Cruz Technology technical support personnel as one of the regions flanked by targeted constructs for Cd73 deletion. For in vivo studies, 5 × 105 MC38Cd73KO cells without or with 2 × 105 MSCs were suspended in 0.2 ml of PBS and inoculated s.c. into the flank of WT mice. Tumors were measured every other day. Five days post-tumor inoculation when tumors were palpable, different groups of mice received various treatments of either monotherapy of individual adenosinergic antagonist, anti-CD73, or combinatorial therapy of both adenosinergic antagonism and CD73 neutralization as described above.

Statistical analysis

Statistical significance was assessed by two-tailed unpaired nonparametric or Student’s t-test using Prism 7 software (GraphPad, CA). A p value of <0.05 was considered significant and was indicated in each figure. Statistical differences in tumor progression between two groups of experimental mice was analyzed via multiple t-test at each tumor measurement time point using Prism 7. The specific p value with relevant statistical analysis used for each study is presented in the figure panel.

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

The RNA-seq data that support Fig. 3 of this study are available at Genes Expression Omnibus (GEO) under the accession number GSE141199 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE141199). All data, including those for supplementary figures, are provided in the compiled Source Data files.

References

  1. 1.

    Colgan, S. P., Eltzschig, H. K., Eckle, T. & Thompson, L. F. Physiological roles for ecto-5’-nucleotidase (CD73). Purinergic Signal. 2, 351–360 (2006).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Beavis, P. A., Stagg, J., Darcy, P. K. & Smyth, M. J. CD73: a potent suppressor of antitumor immune responses. Trends Immunol. 33, 231–237 (2012).

    Article  CAS  Google Scholar 

  3. 3.

    Allard, B., Longhi, M. S., Robson, S. C. & Stagg, J. The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets. Immunol. Rev. 276, 121–144 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Ohta, A. & Sitkovsky, M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414, 916–920 (2001).

    Article  ADS  CAS  Google Scholar 

  5. 5.

    Ohta, A. & Sitkovsky, M. Extracellular adenosine-mediated modulation of regulatory T cells. Front. Immunol. 5, 304 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. 6.

    Zarek, P. E. et al. A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood 111, 251–259 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. 7.

    Leclerc, B. G. et al. CD73 expression is an independent prognostic factor in prostate cancer. Clin. Cancer Res. 22, 158–166 (2016).

    Article  CAS  Google Scholar 

  8. 8.

    Serra, S. et al. CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood 118, 6141–6152 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Turcotte, M. et al. CD73 is associated with poor prognosis in high-grade serous ovarian cancer. Cancer Res. 75, 4494–4503 (2015).

    Article  CAS  Google Scholar 

  10. 10.

    Reinhardt, J. et al. MAPK signaling and inflammation link melanoma phenotype switching to induction of CD73 during immunotherapy. Cancer Res. 77, 4697–4709 (2017).

    Article  CAS  Google Scholar 

  11. 11.

    Maj, T. et al. Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat. Immunol. 18, 1332–1341 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. 12.

    Wang, L. et al. CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J. Clin. Invest. 121, 2371–2382 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Stagg, J. et al. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res. 71, 2892–2900 (2011).

    Article  CAS  Google Scholar 

  14. 14.

    Stagg, J. et al. CD73-deficient mice are resistant to carcinogenesis. Cancer Res. 72, 2190–2196 (2012).

    Article  CAS  Google Scholar 

  15. 15.

    Gascard, P. & Tlsty, T. D. Carcinoma-associated fibroblasts: orchestrating the composition of malignancy. Genes Dev. 30, 1002–1019 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. 16.

    Kalluri, R. The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 16, 582–598 (2016).

    Article  CAS  Google Scholar 

  17. 17.

    Turley, S. J., Cremasco, V. & Astarita, J. L. Immunological hallmarks of stromal cells in the tumour microenvironment. Nat. Rev. Immunol. 15, 669–682 (2015).

    Article  CAS  Google Scholar 

  18. 18.

    Bhowmick, N. A., Neilson, E. G. & Moses, H. L. Stromal fibroblasts in cancer initiation and progression. Nature 432, 332–337 (2004).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  19. 19.

    Orimo, A. et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335–348 (2005).

    Article  CAS  Google Scholar 

  20. 20.

    Ohlund, D., Elyada, E. & Tuveson, D. Fibroblast heterogeneity in the cancer wound. J. Exp. Med. 211, 1503–1523 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. 21.

    Quante, M. et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 19, 257–272 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. 22.

    Dominici, M. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315–317 (2006).

    Article  CAS  Google Scholar 

  23. 23.

    Calon, A. et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat. Genet. 47, 320–329 (2015).

    Article  CAS  Google Scholar 

  24. 24.

    Sadanandam, A. et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat. Med. 19, 619–625 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. 25.

    Malhotra, D. et al. Transcriptional profiling of stroma from inflamed and resting lymph nodes defines immunological hallmarks. Nat. Immunol. 13, 499–510 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. 26.

    Turcotte, M. et al. CD73 promotes resistance to HER2/ErbB2 antibody therapy. Cancer Res. 77, 5652–5663 (2017).

    Article  CAS  Google Scholar 

  27. 27.

    Wu, R. et al. Effects of CD73 on human colorectal cancer cell growth in vivo and in vitro. Oncol. Rep. 35, 1750–1756 (2016).

    Article  CAS  Google Scholar 

  28. 28.

    Wu, X. R. et al. High expression of CD73 as a poor prognostic biomarker in human colorectal cancer. J. Surg. Oncol. 106, 130–137 (2012).

    Article  CAS  Google Scholar 

  29. 29.

    Vaupel, P. & Mayer, A. Hypoxia-driven adenosine accumulation: a crucial microenvironmental factor promoting tumor progression. Adv. Exp. Med. Biol. 876, 177–183 (2016).

    Article  CAS  Google Scholar 

  30. 30.

    Vaupel, P. & Multhoff, G. Adenosine can thwart antitumor immune responses elicited by radiotherapy: therapeutic strategies alleviating protumor ADO activities. Strahlenther. Onkol. 192, 279–287 (2016).

    Article  Google Scholar 

  31. 31.

    Ishii, G., Ochiai, A. & Neri, S. Phenotypic and functional heterogeneity of cancer-associated fibroblast within the tumor microenvironment. Adv. Drug Deliv. Rev. 99, 186–196 (2016).

    Article  CAS  Google Scholar 

  32. 32.

    Pouyssegur, J., Dayan, F. & Mazure, N. M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441, 437–443 (2006).

    Article  ADS  CAS  Google Scholar 

  33. 33.

    Blouw, B. et al. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4, 133–146 (2003).

    Article  CAS  Google Scholar 

  34. 34.

    Synnestvedt, K. et al. Ecto-5’-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J. Clin. Invest. 110, 993–1002 (2002).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. 35.

    Sitkovsky, M. V. et al. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu. Rev. Immunol. 22, 657–682 (2004).

    Article  CAS  Google Scholar 

  36. 36.

    Allard, B., Beavis, P. A., Darcy, P. K. & Stagg, J. Immunosuppressive activities of adenosine in cancer. Curr. Opin. Pharm. 29, 7–16 (2016).

    Article  CAS  Google Scholar 

  37. 37.

    Chen, J. F., Eltzschig, H. K. & Fredholm, B. B. Adenosine receptors as drug targets—what are the challenges? Nat. Rev. Drug Discov. 12, 265–286 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. 38.

    Bezu, L. et al. Combinatorial strategies for the induction of immunogenic cell death. Front. Immunol. 6, https://doi.org/10.3389/fimmu.2015.00187 (2015).

  39. 39.

    Barker, H. E., Paget, J. T., Khan, A. A. & Harrington, K. J. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat. Rev. Cancer 15, 409–425 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. 40.

    Lotti, F. et al. Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A. J. Exp. Med. 210, 2851–2872 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. 41.

    Tommelein, J. et al. Radiotherapy-activated cancer-associated fibroblasts promote tumor progression through paracrine IGF1R activation. Cancer Res. 78, 659–670 (2018).

    Article  CAS  Google Scholar 

  42. 42.

    Samanta, D. et al. Chemotherapy induces enrichment of CD47+CD73+PDL1+ immune evasive triple-negative breast cancer cells. Proc. Natl Acad. Sci. USA 115, E1239–E1248 (2018).

    Article  CAS  Google Scholar 

  43. 43.

    Guo, G., Yu, M., Xiao, W., Celis, E. & Cui, Y. Local activation of p53 in the tumor microenvironment overcomes immune suppression and enhances antitumor immunity. Cancer Res. 77, 2292–2305 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. 44.

    Young, A. et al. Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses. Cancer Cell 30, 391–403 (2016).

    Article  CAS  Google Scholar 

  45. 45.

    Topalian Suzanne, L., Drake Charles, G. & Pardoll Drew, M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450–461 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. 46.

    Wei, S. C. et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell 170, 1120–1133.e17 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. 47.

    Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423–1437 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. 48.

    Guo, G. et al. Trp53 inactivation in the tumor microenvironment promotes tumor progression by expanding the immunosuppressive lymphoid-like stromal network. Cancer Res. 73, 1668–1675 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. 49.

    Jin, D. et al. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res. 70, 2245–2255 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. 50.

    Freeman, M. R., Li, Q. & Chung, L. W. Can stroma reaction predict cancer lethality? Clin. Cancer Res. 19, 4905–4907 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. 51.

    Mittal, D. et al. Adenosine 2B receptor expression on cancer cells promotes metastasis. Cancer Res. 76, 4372–4382 (2016).

    Article  CAS  Google Scholar 

  52. 52.

    Mediavilla-Varela, M. et al. Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth. Cancer Biol. Ther. 14, 860–868 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. 53.

    Wirsdorfer, F. et al. Extracellular adenosine production by ecto-5’-nucleotidase (CD73) enhances radiation-induced lung fibrosis. Cancer Res. 76, 3045–3056 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. 54.

    Loi, S. et al. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc. Natl Acad. Sci. USA 110, 11091–11096 (2013).

    Article  ADS  Google Scholar 

  55. 55.

    Hatfield, S. M. et al. Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1alpha-dependent and extracellular adenosine-mediated tumor protection. J. Mol. Med. 92, 1283–1292 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. 56.

    Stagg, J. et al. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc. Natl Acad. Sci. USA 107, 1547–1552 (2010).

    Article  ADS  Google Scholar 

  57. 57.

    Cekic, C. et al. Adenosine A2B receptor blockade slows growth of bladder and breast tumors. J. Immunol. 188, 198–205 (2012).

    Article  CAS  Google Scholar 

  58. 58.

    Marisa, L. et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med. 10, e1001453 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. 59.

    Hegde, P. S., Karanikas, V. & Evers, S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin. Cancer Res. 22, 1865–1874 (2016).

    Article  CAS  Google Scholar 

  60. 60.

    Beavis, P. A. et al. Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. J. Clin. Investig. 127, 929–941 (2017).

    Article  Google Scholar 

  61. 61.

    Antonioli, L. et al. Switching off CD73: a way to boost the activity of conventional and targeted antineoplastic therapies. Drug Discov. Today 22, 1686–1696 (2017).

    Article  CAS  Google Scholar 

  62. 62.

    Trapnell, C., Pachter, L. & Salzberg, S. L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105–1111 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. 63.

    Trapnell, C. et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat. Biotechnol. 28, 511–515 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We would like to thank Ms. Arleen Lopez and the Georgia Cancer Center Biorepository team for biospecimen acquisition and specimen preparation for this research. This study is supported in part by R01CA169133 from NCI/NIH, R21DE028716 from NIDCR, and funds from GRU Cancer Center to Y.C. and NCI grants R01CA103320 and R01CA211229 to D.M. The RNA sequencing Data was generated in the Genome Sequencing Facility which is supported by UT Health San Antonio with NIH Shared Instrument grant 1S10OD021805-01 (S10 grant to Z. Lai for acquisition of HiSeq 3000) and Greehey Children’s Cancer Research Institute.

Author information

Affiliations

Authors

Contributions

M.Y. conceived the study, performed the experiments, analyzed and interpreted the results. G.G., L.H., L.D., C.-S.C., B.R.A., M.C., and N.X. performed experiments or provided technical assistance. A.S.A., R.B., P.C.R., A.M., H.S., and D.M. provided crucial scientific and technical advice and resource for this study. Y.C. conceived and supervised the study, analyzed and interpreted the results, and wrote the manuscript.

Corresponding author

Correspondence to Yan Cui.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Peer review information Nature Communications thanks Chris Madsen and John Stagg for their contribution to the peer review of this work.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Yu, M., Guo, G., Huang, L. et al. CD73 on cancer-associated fibroblasts enhanced by the A2B-mediated feedforward circuit enforces an immune checkpoint. Nat Commun 11, 515 (2020). https://doi.org/10.1038/s41467-019-14060-x

Download citation

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing